

3FW

(Substitute) PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

16

Application Number

10/782,968

Filing Date

February 20, 2004

First Named Inventor

Kevin J. Williams

Art Unit

1642

Examiner Name

Attorney Docket Number

W1107/20009

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	- PTO Form 1449A and attached references cited
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	- Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

"Total Number of Pages in This Submission" above does not include the references cited in the PTO Form 1449A.

Please charge Attorney Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., Customer No. 03000		
Signature	<i>Allan H. Fried</i>		
Printed name	Allan H. Fried		
Date	August 1, 2005	Reg. No.	31,253

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	<i>Allan H. Fried</i>		
Typed or printed name	Allan H. Fried	Date	31,253

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION**

Applicants: Kevin J. Williams
Serial No: 10/782,968 Group Art Unit: 1642
Filed: February 20, 2004 Examiner:
Att. Docket No.: W1107/20009 Confirmation No.: 9607
For: THROMBOSPONDIN FRAGMENTS AND USES THEREOF IN
CLINICAL ASSAYS FOR CANCER AND GENERATION OF
ANTIBODIES AND OTHER BINDING AGENTS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the references are prior art with respect to this application.

This Information Disclosure Statement is being filed within three months of the filing date of a national application other than a CPA under 37 CFR § 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of an RCE under 37 CFR § 1.114. No certification or fee is required. 37 CFR § 1.97(b).

Application No. 10/782,968
IDS dated August 1, 2005

The reference US Patent 5,750,502 was cited in the International Search Report of a corresponding international application. A copy of the International Search Report is enclosed.

Respectfully submitted,


CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

August 1, 2005

Please charge or credit our Account
No. 03-0075 as necessary to effect
entry and/or ensure consideration of
this submission.

By Allan H. Fried

Allan H. Fried
Registration No. 31,253
Customer No. 03000
(215) 567-2010
Attorneys for Applicant



Please type a plus sign (+) inside this box →

Form 1449A/PTO (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/782,968
				Filing Date	February 20, 2004
				First Named Inventor	Kevin J. Williams
				Group Art Unit	1642
				Examiner Name	
				Attorney Docket Number Customer No.	W1107/20009 03000
Sheet	1	of	13		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	AA	4,820,505		Ginsberg, et al.	04/11/1989	
	AB	4,610,960		Mosher	09/09/1986	
	AC	5,686,583		Bosslet, et al.	11/11/1997	
	AD	5,256,538		Aiken, et al.	10/26/1993	
	AE	5,192,744		Bouck, et al.	03/09/1993	
	AF	6,239,110		Eyal, et al.	05/29/2001	
	AG	5,654,277		Eyal, et al.	08/05/1997	
	AH	5,840,692		Deutsch, et al.	11/24/1998	
	AI	6,051,549		Roberts, et al.	04/18/2000	
	AJ	5,753,517		Brooks, et al.	05/19/1998	
	AK	5,840,507		Fruehauf	11/24/1998	
	AL	6,339,062		Williams, et al.	01/15/2002	
	AM	5,750,502		Jessell, et al.	05/12/1998	
	AN	2001/0041670		Simantov, et al.	11/15/2001	
	AO	2002/0197697		Abdelouahed, et al.	12/26/2002	
	AP	2003/0180295		Tuszynski, et al.	09/25/2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
	AQ		WO 01/05968	Tuszynski, et al.	01/25/2001	
	AR		International Search Report PCT/US03/260 23	Williams	08/20/2003	

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-----------------------	-------------	--	---

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known			
			Application Number	10/782,968		
			Filing Date	February 20, 2004		
			First Named Inventor	Kevin J. Williams		
			Group Art Unit	1642		
			Examiner Name			
			Attorney Docket Number Customer No.	W1107/20009 03000		
Sheet	2	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	AS	Baenziger NL <i>et al.</i> Isolation and properties of a thrombin-sensitive protein of human platelets. J. Biol. Chem., 1972. 247:2723-2731.	
	AT	Lawler JW <i>et al.</i> Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem., 1978. 253(23):8609-8616. (Abstract only)	
	AU	Wallinder L <i>et al.</i> Rapid removal to the liver of intravenously injected lipoprotein lipase. Biochem. Biophys. Acta, 1979. Oct 26; 575(1):166-173. (Abstract only)	
	AV	Margossian SS <i>et al.</i> Physical characterization of platelet thrombospondin. J. Biol. Chem., 1981. 256(14):7495-7500.	
	AW	Saglio SD <i>et al.</i> Use of a radioimmunoassay to quantify thrombospondin. Blood, 1982. Jan; 59(1):162-166. (Abstract only)	
	AX	Mosher DF <i>et al.</i> Synthesis and secretion of thrombospondin by cultured human endothelial cells. J. Cell Biol., 1982. 93(2):343-348.	
	AY	Dawes J <i>et al.</i> A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb. Res., 1983. March 15; 29:569-581.	
	AZ	Jaffe EA <i>et al.</i> Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc. Natl. Acad. Sci., USA, 1983. Feb; 80(4):998-1002.	
	BA	Prowse CV <i>et al.</i> A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb. Haemost., 1984. Feb 28; 51(1):110-114. (Abstract only)	
	BB	Mumby SM <i>et al.</i> Interactions of thrombospondin with extracellular matrix proteins: selective binding to type V collagen. J. Cell Biol., 1984. 98(2): 646-652. (Abstract only)	
	BC	Coligan, JE and Slayter HS. Structure of thrombospondin. J. Biol. Chem., 1984. 259:3944-3948.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known			
			Application Number	10/782,968		
			Filing Date	February 20, 2004		
			First Named Inventor	Kevin J. Williams		
			Group Art Unit	1642		
			Examiner Name			
			Attorney Docket Number Customer No.	W1107/20009 03000		
Sheet	3	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	BD	Dixit VM <i>et al.</i> Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin. J Biol Chem, 1984. 259:10100-10105. (Abstract only)	
	BE	Lane DA <i>et al.</i> Detection of enhanced in vivo platelet alpha-granule release in different patient groups—comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays. Thromb. Haemost., 1984. Oct 31; 52(2):183-187. (Abstract only)	
	BF	Lahav J <i>et al.</i> Thrombospondin interactions with fibronectin and fibrinogen. Mutual inhibition in binding. Eur. J. Biochem., 1984. Nov 15; 145(1):151-156. (Abstract only)	
	BG	Silverstein RL <i>et al.</i> Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J. Clin. Invest., 1984. Nov; 74(5):1625-1633. (Abstract only)	
	BH	Lawler J <i>et al.</i> The structure of human platelet thrombospondin. J. Biol. Chem., 1985. 260:3762-3772.	
	BI	Roberts DD <i>et al.</i> Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature, 1985. 318(6041):64-66. (Abstract only)	
	BJ	Jaffe EA <i>et al.</i> Monocytes and macrophages synthesize and secrete thrombospondin. Blood, 1985. Jan; 65(1):79-84. (Abstract only)	
	BK	Dixit VM <i>et al.</i> Effects of anti-thrombospondin monoclonal antibodies on the agglutination of erythrocytes and fixed, activated platelets by purified thrombospondin. Biochemistry, 1985. Jul 30; 24(16):4270-4275.	
	BL	Silverstein RL <i>et al.</i> Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J. Biol. Chem., 1985. 260(18):10346-10352.	
	BM	Galvin NJ <i>et al.</i> Mapping of epitopes for monoclonal antibodies against human platelet thrombospondin with electron microscopy and high sensitivity amino acid sequencing. J. Cell Biol., 1985. 101(4):1434-1441.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known			
			Application Number	10/782,968		
			Filing Date	February 20, 2004		
			First Named Inventor	Kevin J. Williams		
			Group Art Unit	1642		
			Examiner Name			
			Attorney Docket Number Customer No.	W1107/20009 03000		
Sheet	4	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	BN	Trzeciak MC <i>et al.</i> Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. <i>Thromb. Res.</i> , 1985. Oct 1; 40(1):121-128. (Abstract only)	
	BO	Tuszynski GP <i>et al.</i> The interaction of human platelet thrombospondin with fibrinogen. Thrombospondin purification and specificity of interaction. <i>J. Biol. Chem.</i> , 1985. 260(22):12240-12245.	
	BP	Miller WR <i>et al.</i> Platelet-associated proteins in human breast cyst fluids. <i>Clin. Chim. Acta</i> , 1985. Oct 31; 152(1-2):37-42. (Abstract only)	
	BQ	Switalska HI <i>et al.</i> Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and beta-thromboglobulin antigen secretion and clearance from the circulation. <i>J. Lab. Clin. Med.</i> , 1985. Dec; 106(6):690-700. (Abstract only)	
	BR	Kaplan KL <i>et al.</i> Plasma levels of platelet secretory proteins. <i>Crit. Rev. Oncol. Hematol.</i> , 1986. 5(3):235-255. (Abstract only)	
	BS	Dixit VM <i>et al.</i> Monoclonal antibodies that recognize calcium-dependent structures of human thrombospondin. Characterization and mapping of their epitopes. <i>J. Biol. Chem.</i> , 1986, 261(4):1962-1968.	
	BT	Wolff R <i>et al.</i> Interaction of thrombospondin with resting and stimulated human platelets. <i>J. Biol. Chem.</i> , 1986. 261(15):6840-6846.	
	BU	Kao KJ <i>et al.</i> A monoclonal antibody-based enzyme-linked immunosorbent assay for quantitation of plasma thrombospondin. <i>Am. J. Clin. Pathol.</i> , 1986. Sep; 86(3):317-323. (Abstract only)	
	BV	Lawler, J., <i>et al.</i> Thrombin and chymotrypsin interactions with thrombospondin. <i>Ann N Y Acad. Sci.</i> 1986; 485:273-87.	
	BW	Tuszynski GP <i>et al.</i> Methods of studying platelet-secreted proteins and the platelet cytoskeleton, Alan R. Liss, Inc., New York, 1987. 4:267-286.	
	BX	Frazier WA. Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cell. <i>J. Cell Biol.</i> , 1987. 105(2):625-632.	
	BY	Asch AS <i>et al.</i> Isolation of the thrombospondin membrane receptor. <i>J. Clin. Invest.</i> , 1987. Apr; 79:1054-1076. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known		
			Application Number	10/782,968	
			Filing Date	February 20, 2004	
			First Named Inventor	Kevin J. Williams	
			Group Art Unit	1642	
			Examiner Name		
			Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	5	of	13		
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T

	BZ	Galvin NJ <i>et al.</i> Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J. Cell Biol., 1987. 104(5):1413-1422. (Abstract only)	
	CA	Dardik R <i>et al.</i> The structure of endothelial cell thrombospondin. Characterization of the heparin-binding domains. Eur. J. Biochem., 1987. Oct 15; 168(2):347-355. (Abstract only)	
	CB	McCrohan MB <i>et al.</i> Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis. Thromb. Haemost., 1987. Oct 28; 58(3):850-852. (Abstract only)	
	CC	Walz, DA, <i>et al.</i> , Binding of thrombospondin to immobilized ligands: specific interaction with fibrinogen, plasminogen, histidine-rich glycoprotein, and fibronectin, Semin Throm Hemost. 13(3):317-325 1987.	
	CD	Legrand C <i>et al.</i> Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur. J. Biochem., 1988. Jan 15; 171(1-2):393-399. (Abstract only)	
	CE	Majack RA <i>et al.</i> Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J. Cell Biol. 1988. Feb.; 106: 415-422.	
	CF	Dawes J <i>et al.</i> Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb. Haemost., 1988. Apr 8; 59(2):273-276. (Abstract only)	
	CG	Clezardin P <i>et al.</i> Complex formation of human thrombospondin with osteonectin. Eur. J. Biochem., 1988. Aug 1; 175:275-284. (Abstract only)	
	CH	Asch AS and Nachman RL. Thrombospondin: phenomenology to function. Prog. Hemost. Thromb., 1989. 9:157-176. (Abstract only)	
	CI	Gehron-Robey P <i>et al.</i> Thrombospondin is an osteoblast-derived component of mineralized extracellular matrix. J. Cell Biol., 1989. 108:719-727.	
	CJ	Cardin AD and Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis, 1989. Jan-Feb; 9(1):21-32. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known			
			Application Number	10/782,968		
			Filing Date	February 20, 2004		
			First Named Inventor	Kevin J. Williams		
			Group Art Unit	1642		
			Examiner Name			
			Attorney Docket Number Customer No.	W1107/20009 03000		
Sheet	6	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	CK	Bacon-Baguley T <i>et al.</i> Thrombospondin binding to specific sequences within the α - and β -chains of fibrinogen. J. Biol. Chem., 1990. 265(4):2317-23.	
	CL	Silverstein RL <i>et al.</i> Thrombospondin forms complexes with single-chain and two-chain forms of urokinase. J. Biol. Chem., 1990. 265(19):11289-11294. (Abstract only)	
	CM	Good DJ <i>et al.</i> A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci., USA, 1990. Sep; 87:6624-6628.	
	CN	Gawaz MP <i>et al.</i> Effects of hemodialysis on platelet-derived thrombospondin. Kidney Int., 1991. Aug; 40(2):257-265. (Abstract only)	
	CO	Dardik R <i>et al.</i> Cell-binding domain of endothelial cell thrombospondin: localization to the 70kDa core fragment and determination of binding characteristics. Biochemistry, 1991. Sep 24; 30(38):9378-9386.	
	CP	Sage EH and Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J. Biol. Chem., 1991. 266(23):14831-14834.	
	CQ	Frazier WA. Thrombospondins. Current. Opin. Cell Biol., 1991. 3(5): 792-799. (Abstract only)	
	CR	Tuszynski GP <i>et al.</i> Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins. J. Cell Biol., 1992. 116(1):209-217.	
	CS	Lawler J <i>et al.</i> Expression and mutagenesis of thrombospondin. Biochemistry, 1992. Feb 4; 31(4):1173-1180.	
	CT	Prater CA <i>et al.</i> The properdin-like type I repeats of human thrombospondin contain a cell attachment site. J. Cell Biol., 1991. 112(5):1031-1040.	
	CU	Osterhout DJ <i>et al.</i> Thrombospondin promotes process outgrowth in neurons from the peripheral and central nervous systems. Devel. Biol, 1992. 150(2):256-265. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known		
			Application Number	10/782,968	
			Filing Date	February 20, 2004	
			First Named Inventor	Kevin J. Williams	
			Group Art Unit	1642	
			Examiner Name		
			Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	7	of	13		
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T

	CV	Tuszynski GP <i>et al.</i> Thrombospondin levels in patients with malignancy. <i>Thromb. Haemost.</i> , 1992. 67(6):607-611. (Abstract only)	
	CW	Kosfeld MD <i>et al.</i> Identification of active peptide sequences in the carboxyl-terminal cell binding domain of human thrombospondin-1. <i>J. Biol. Chem.</i> , 1992. 267(23):16230-16236.	
	CX	Zafar RS <i>et al.</i> Localization of two binding domains for thrombospondin within fibronectin. <i>Arch. Biochem. Biophys.</i> , 1992. Sep; 297(2):271-276. (Abstract only)	
	CY	Soga T <i>et al.</i> Analysis of adhesive proteins on the surface of platelets from the patients with lung cancer: studies in histological type and clinical stage. <i>Rinsho Ketsueki</i> , 1992. Sep; 33(9):1121-1127. [Article in Japanese] (English Abstract only)	
	CZ	Takagi T <i>et al.</i> A single chain 19-kDa fragment from bovine thrombospondin binds to type V collagen and heparin. <i>J. Biol. Chem.</i> , 1993. 268(21):15544-15549.	
	DA	Murphy-Ullrich JE <i>et al.</i> Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. <i>J. Biol. Chem.</i> , 1993. 268(35): 26784-26789. (Abstract only)	
	DB	Lawler J <i>et al.</i> Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. <i>J. Cell Biol.</i> , 1993. 120(4):1059-1067.	
	DC	Sipes JM <i>et al.</i> Inhibition of fibronectin binding and fibronectin-mediated cell adhesion to collagen by a peptide from the second type I repeat of thrombospondin. <i>J. Cell Biol.</i> , 1993. 121(2):469-477.	
	DD	Tolsma <i>et al.</i> Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. <i>J. Cell Biol.</i> , 1993. 122(2):497-511.	
	DE	Huang SW <i>et al.</i> The relationship between plasma thrombospondin level and the clinical course of atopic dermatitis. <i>Allergy Proc.</i> , 1993. Sep-Oct; 14(5):357-361. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known		
			Application Number	10/782,968	
			Filing Date	February 20, 2004	
			First Named Inventor	Kevin J. Williams	
			Group Art Unit	1642	
			Examiner Name		
			Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	8	of	13		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-----------------------	-------------	---	---

	DF	Zammit A <i>et al.</i> Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. <i>Thromb. Haemost.</i> , 1993. Dec 20; 70(6):951-958. (Abstract only)	
	DG	Morandi V <i>et al.</i> Characterization of a novel monoclonal antibody (V58A4) raised against a recombinant NH ₂ -terminal heparin-binding fragment of human endothelial cell thrombospondin. <i>FEBS Lett</i> , 1994. 346(2-3):156-160. (Abstract only)	
	DH	Bayraktar M. <i>et al.</i> Platelet Factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes melitus patients. <i>J. Int. Med. Res.</i> , 1994, Mar-Apr; 22(2):90-94. (Abstract only)	
	DI	Nathan FE <i>et al.</i> Plasma thrombospondin levels in patients with gynecological malignancies. <i>Cancer</i> , 1994. Jun 1; 73(11):2853-2858. (Abstract only)	
	DJ	Shen D <i>et al.</i> Effects of hypoxia on platelet activation in pilots. <i>Aviat Space Environ. Med.</i> , 1994. Jul; 65(7):646-648. (Abstract only)	
	DK	Schultz-Cherry S <i>et al.</i> The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. <i>J. Biol. Chem.</i> , 1994. 269(43):26783-26788.	
	DL	Adams, JC, <i>et al.</i> The Thrombospondin Gene Family, Springer-Verlag: New York, 1995, pp.1-9, 11-56.	
	DM	Huang SW <i>et al.</i> Plasma thrombospondin levels in sheep with allergic asthma. <i>Chest</i> , 1996. Jun; 109(6):1614-1617.	
	DN	Qian X <i>et al.</i> Expression of thrombospondin-1 in cancer: a role in tumor progression. <i>Proc. Soc. Exp. Biol. Med.</i> , 1996. Jul; 212(3):199-207.	
	DO	Levine DM and William KJ. Automated measurement of mouse apolipoprotein B: convenient screening tool for mouse models of atherosclerosis. <i>Clin. Chem.</i> , 1997. 43(4):669-674. (Abstract only)	
	DP	Partin AW <i>et al.</i> Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. <i>JAMA</i> , 1997. 277(18):1445-1451. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/782,968	
				Filing Date	February 20, 2004	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1642	
				Examiner Name		
				Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	9	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	DQ	Yamashita Y <i>et al.</i> Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer, 1998. Feb 15; 82(4):632-638. (Abstract only)	
	DR	Goundis D <i>et al.</i> Properdin, the terminal complement components, thrombospondin and the circumsporozoite protein of malaria parasites contain similar sequence motifs. Nature, 1988. Sep 1; 335(6185):82-5. (Abstract only)	
	DS	Ozatli D <i>et al.</i> Circulating thrombomodulin, thrombospondin, and fibronectin in acute myeloblastic leukemias. Haematologia (Budap.), 1999. 29(4):277-283. (Abstract only)	
	DT	Kanda S <i>et al.</i> Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp. Cell Res., 1999. 252(2):262-272.	
	DU	Panetti TS <i>et al.</i> Interaction of recombinant procollagen and properdin modules of thrombospondin-1 with heparin and fibrinogen/fibrin. J. Biol. Chem., 1999. 274(1):430-437.	
	DV	Stancik R <i>et al.</i> Plasma levels of TPA, PAI-1 and thrombospondin in patients with systemic vasculitis. Clin. Appl. Thromb. Hemost., 1999. Apr; 5(2):140-141.	
	DW	Roth JJ <i>et al.</i> Thrombospondin 1 and its specific cysteine-serine-valine-threonine-cysteine-cycline receptor in fetal wounds. Ann. Plast. Surg., 1999. May; 42(5):553-563. (Abstract only)	
	DX	Altun B <i>et al.</i> Thrombopoietin and thrombospondin in renal allograft recipients. Blood Coagul. Fibrinolysis, 1999. Jul; 10(5):233-237. (Abstract only)	
	DY	Krutzsch HC <i>et al.</i> Identification of an $\alpha(3)\beta(1)$ integrin recognition sequence in thrombospondin-1. J. Biol. Chem., 1999. 274(34):24080-24086.	
	DZ	Nomura S <i>et al.</i> Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies. Thromb. Res., 1999. Sep 1; 95:205-213.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known		
			Application Number	10/782,968	
			Filing Date	February 20, 2004	
			First Named Inventor	Kevin J. Williams	
			Group Art Unit	1642	
			Examiner Name		
			Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	10	of	13		
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T

	EA	Michelson AD and Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr. Opin. Hematol., 1999. Sep; 6(5):342-348.	
	EB	Chen et al. Cartilage oligomeric matrix protein is a calcium-binding protein, and a mutation in its type 3 repeats causes conformational changes. J. Biol. Chem., 2000. 275(34):26538-26544.	
	EC	Voland C <i>et al.</i> Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1. J. Bone Miner. Res., 2000. Feb; 15(2):361-368. (Abstract only)	
	ED	Carron JA <i>et al.</i> A CD36-binding peptide from thrombospondin-1 can stimulate resorption by osteoclasts in vitro. Biochem. Biophys. Res. Commun., 2000. Apr 21; 270(3):1124-1127. (Abstract only)	
	EE	Hayden K <i>et al.</i> Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application. Ann. Clin. Biochem., 2000. May; 37 (Pt. 3):319-325.	
	EF	Bergseth G <i>et al.</i> A novel enzyme immunoassay for plasma thrombospondin. Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo. Thromb. Res., 2000. Jul 1; 99:41-50.	
	EG	Pini A and Bracci L. Phage display of antibody fragments. Curr. Protein Pept.Sci., 2000.Sep; 1(2):155-169. (Abstract only)	
	EH	Rusnati M <i>et al.</i> Thrombospondin-1/HIV-1 TAT protein interaction: modulation of the biological activity of extracellular TAT. FASEB J. 2000. Oct; 14:1917-1930.	
	EI	Vanguri, VK., <i>et al.</i> Thrombospondin-1 binds to polyhistidine with high affinity and specificity, Biochemical Society. 2000.	
	EJ	Bonnefoy A <i>et al.</i> A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen and GPIIb/IIIa receptor. J. Biol. Chem., 2001. 276(8):5605-5612.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known		
			Application Number	10/782,968	
			Filing Date	February 20, 2004	
			First Named Inventor	Kevin J. Williams	
			Group Art Unit	1642	
			Examiner Name		
			Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	11	of	13		
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T

	EK	Damas C <i>et al.</i> The 33-kDa platelet alpha-granule membrane protein (GMP-33) is an N-terminal proteolytic fragment of thrombospondin. Thromb. Haemost. Sep;86(3):887-893. (Abstract only)	
	EL	Fraipont F <i>et al.</i> Thrombospondins and tumor angiogenesis. Trend Mol. Med., 2001. 7:401-407.	
	EM	Hofsteenge J <i>et al.</i> C-mannosylation and O-fucosylation of the thrombospondin type 1 module. J. Biol. Chem., 2001. 276(9):6485-6498.	
	EN	Hamaguchi N <i>et al.</i> Aptamer beacons for the direct detection of proteins. Anal. Biochem., 2001. Jul 15; 294(2):126-131. (Abstract only)	
	EO	Nomura S <i>et al.</i> Function and clinical significance of platelet-derived microparticles. Int. J. Hematol., 2001. Dec; 74(4):397-404. (Abstract only)	
	EP	Simantov, R., <i>et al.</i> Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1, J. Clin. Investig., January 2001, 107(1):45-52.	
	EQ	Qian MD <i>et al.</i> Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a recombinant phage display library. Hum. Antibodies, 2002. 11(3):97-105. (Abstract only)	
	ER	Zhang W <i>et al.</i> Production and characterization of human monoclonal anti-idiotypic antibodies to anti-dsDNA antibodies. Lupus, 2002. 11(6):362-369. (Abstract only)	
	ES	Asvadi P <i>et al.</i> Expression and functional analysis of recombinant scFV and diabody fragments with specificity for human RhD. J. Mol. Recognit., 2002. 15:321-330. (Abstract only)	
	ET	Rau D <i>et al.</i> Single-chain Fv antibody-alkaline phosphatase fusion proteins produced by one-step cloning as rapid detection tools for ELISA. J. Immunoassay Immunochem., 2002. 23(2):129-143. (Abstract only)	
	EU	Flores-Flores C <i>et al.</i> Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library. J. Neural. Transm. Suppl., 2002. 62:165-179. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/782,968	
				Filing Date	February 20, 2004	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1642	
				Examiner Name		
				Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	12	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	EV	Stamey TA <i>et al.</i> Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urology, 2002. Jan; 167(1):103-111. (Abstract only)	
	EW	Baglia FA <i>et al.</i> Factor XI binding to the glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J.Biol. Chem., 2002. 277(3):1662-8.	
	EX	Rau D <i>et al.</i> Cloning, functional expression and kinetic characterization of pesticide-selective Fab fragment variants derived by molecular evolution of variable antibody genes. Anal. Bioanal. Chem., 2002. Jan; 372(2):261-267. (Abstract only)	
	EY	Nathan S <i>et al.</i> Phage display of recombinant antibodies toward Burkholderia pseudomallei exotoxin. J. Biochem. Mol. Biol. Biophys., 2002. Feb; 6(1):45-53. (Abstract only)	
	EZ	Baek H <i>et al.</i> An improved helper phage system for efficient isolation of specific antibody molecules in phage display. Nucleic Acids Res., 2002. 30(5):e18.	
	FA	Zhou B <i>et al.</i> Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat. Proc. Natl. Acad. Sci., USA, 2002. Apr 16;99(8):5241-5246. (Abstract only)	
	FB	Gurney D <i>et al.</i> A reliable plasma marker of platelet activation: Does it exist? Am. J. Hematol., 2002. Jun; 70(2):139-144. (Abstract only)	
	FC	Reich N <i>et al.</i> Generation and characterization of human monoclonal scFv antibodies against Helicobacter pylori antigens. Infect. Immun., 2002. Aug; 70(8):4158-4164.	
	FD	O'Connell D <i>et al.</i> Phage versus phagemid libraries for generation of human monoclonal antibodies. J. Mol. Biol., 2002. Aug 2; 321(1):49-56. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)			Complete if Known		
			Application Number	10/782,968	
			Filing Date	February 20, 2004	
			First Named Inventor	Kevin J. Williams	
			Group Art Unit	1642	
			Examiner Name		
			Attorney Docket Number Customer No.	W1107/20009 03000	
Sheet	13	of	13		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-----------------------	-------------	---	---

	FE	Lu D <i>et al.</i> Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J. Immunol. Methods, 2002. Sep 15; 267(2):213-226. (Abstract only)	
	FF	Oelschlaeger P <i>et al.</i> Fluorophor-linked immunosorbent assay: a time- and cost-saving method for the characterization of antibody fragments using a fusion protein of a single-chain antibody fragment and enhanced green fluorescent protein. Anal. Biochem, 2002. Oct 1; 309(1):27-34. (Abstract only)	
	FG	Gao C <i>et al.</i> A method for the generation of combinatorial antibody libraries using pIX phage display. Proc. Natl. Acad. Sci., USA, 2002. Oct 1; 99(20):12612-12616. (Abstract only)	
	FH	Lee KJ <i>et al.</i> Phage-display selection of a human single-chain fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen. J. Am. Chem. Soc., 2002. Oct 23; 124(42):12439-12446. (Abstract only)	
	FI	Sinacola JR and Robinson AS. Rapid folding and polishing of single-chain antibodies from Escherichia coli inclusion bodies. Protein Expr. Purif., 2002. Nov; 26(2):301-308. (Abstract only)	
	FJ	Epel M <i>et al.</i> A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Cancer Immunol. Immunother., 2002. 51(10):565-573. (Abstract only)	
	FK	Schlattner U <i>et al.</i> Isoenzyme-directed selection and characterization of anti-creatine kinase single chain Fv antibodies from a human phage display library. Biochem. Biophys. Acta, 2002. Dec 12; 1579(2-3):124-132. (Abstract only)	

EXAMINER

DATE CONSIDERED

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.